FAQs

Q. Are HepaLife shares publicly traded? If so, where are they available?

A. Yes, HepaLife Technologies, Inc. is a developer of cell-based medical technologies, publicly traded under the ticker symbol:

HPLF on the OTCBB exchange in the USA
WKN 500625 (ISIN: US42689P1049) in Germany

Q. What is HepaLife’s CUSIP number?

A. HepaLife’s CUSIP number is 98950 L107

Q. How do investors acquire HepaLife shares for their portfolios?

A. Please see below for the following options:

HPLF common shares can only be purchased through a registered investment advisor, stockbroker, or financial services firm and/or bank that provides share brokerage services.
Shares may not be purchased directly through the Company at this time.
Should you or your broker require additional information, kindly contact HepaLife Investor Relations at 1-800-518-4879 or by using our website form (click here) to email us.
Investor education information is available through the Securities and Exchange Commission’s Office of Investor Education at http://www.sec.gov/investor.shtml.

Q. Who is the Company’s transfer agent?

A. HepaLife’s transfer agent is Holladay Stock Transfer, Inc.. The transfer agent is able to assist investors who have misplaced, lost, or destroyed share certificates. Should you or your broker need to get in touch with HepaLife’s transfer agent, kindly refer to the contact information below:

Holladay Stock Transfer, Inc.
2939 N. 67th Place
Scottsdale, AZ 85251
Tel: (480) 481-3940 Fax: (480) 481-3941

Q. What are the Company’s quarterly reporting periods and when is the fiscal year-end?

A. HepaLife’s quarterly reporting periods are as listed below:

Q1 January 1 thru March 31
Q2 April 1 thru June 30
Q3 July 1 thru September 31
Q4 October 1 thru December 31
HepaLife’s fiscal year ends December 31

Q. When and where was HepaLife Technologies, Inc. originally incorporated?

A. HepaLife Technologies, Inc. was first incorporated as Zeta Corporation in the State of Florida, effective October 21, 1997.

Q. How can I receive updated financial information on HepaLife?

A. HepaLife routinely files financial reports and discloses financial information as per legal requirements stipulated by the Securities Exchange Commission (SEC). The Company’s filings may be viewed on this web site’s ‘SEC Filings’ section or at the SEC web site at http://www.sec.gov.

Q. When and where does the HepaLife annual general meeting take place?

A. In accordance with SEC rules, HepaLife shareholders are formally provided advance notice of the annual general meeting (AGM) each year. The AGM time, location, agenda and other information may be obtained by contacting the Company’s Investor Relations department at 1-800-518-4879 or by using our website form (click here) to email us.

Send Page to a Friend Investor Alerts